{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:58:25Z","timestamp":1792839505769,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbmt.2020.08.006","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T21:56:33Z","timestamp":1597096593000},"page":"2089-2097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome (VOD\/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide"],"prefix":"10.1016","volume":"26","author":[{"given":"Ignacio","family":"G\u00f3mez-Centuri\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Bail\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillen","family":"Oarbeascoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo \u00c1lvarez","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Echenagusia","family":"Boyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Barzallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"D\u00edez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.08.006_bib0001","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0002","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2013a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0004","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Veno-occlusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0006","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0007","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0008","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bmt.2014.7","article-title":"Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome","volume":"49","author":"Nagler","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0009","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.bbmt.2020.08.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26519","article-title":"Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites","volume":"64","author":"Toksvang","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0011","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0012","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2014.168","article-title":"Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen","volume":"49","author":"Tsirigotis","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0013","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0014","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the International Compassionate-Use Program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0015","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0016-5085(03)00377-9","article-title":"Transjugular intrahepatic portosystemic shunt: current status","volume":"124","author":"Boyer","year":"2003","journal-title":"Gastroenterology"},{"issue":"suppl 3","key":"10.1016\/j.bbmt.2020.08.006_bib0016","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1097\/MCG.0b013e318157e500","article-title":"The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension","volume":"41","author":"Colombato","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0017","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bmt.1702386","article-title":"Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation","volume":"25","author":"Azoulay","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1034\/j.1600-0676.2001.210105.x","article-title":"Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation\u2014role of transjugular intrahepatic portosystemic shunt (TIPS)","volume":"21","author":"Zenz","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0019","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-2005-858957","article-title":"TIPS for veno-occlusive disease following stem cell transplantation","volume":"44","author":"Schoppmeyer","year":"2006","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0021","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0022","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ejh.13103","article-title":"Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes","volume":"101","author":"Gayoso","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0023","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/bmt.2016.115","article-title":"Busulfan-based reduced-intensity conditioning regimens for haploidentical transplantation in relapsed\/refractory Hodgkin lymphoma: Spanish multicenter experience","volume":"51","author":"Gayoso","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0024","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0025","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00277-019-03698-8","article-title":"Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation","volume":"98","author":"Cai","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0026","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","article-title":"Risk score for development of veno-occlusive disease after allogeneic hematopoietic cell transplant","volume":"24","author":"Strouse","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0027","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00261-005-0336-2","article-title":"Expanded PTFE-covered stent-grafts in the treatment of transjugular intrahepatic portosystemic shunt (TIPS) stenoses and occlusions","volume":"30","author":"Echenagusia","year":"2005","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0028","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone-marrow transplantation (first of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0029","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/j.seminoncol.2012.09.003","article-title":"Haploidentical bone marrow transplantation without T-cell depletion","volume":"39","author":"Chang","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0030","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.bbmt.2014.07.029","article-title":"Are alternative donors really still \u201calternative?\u201d","volume":"20","author":"Kanakry","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0032","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","article-title":"Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors","volume":"20","author":"Di Stasi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0033","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0034","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2015.283","article-title":"Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes","volume":"51","author":"Yakushijin","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0035","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/bloodadvances.2019000236","article-title":"Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation","volume":"3","author":"Kwon","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0036","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0037","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10245332.1999.11746478","article-title":"BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study","volume":"4","author":"Morado","year":"2000","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0038","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12185-014-1578-y","article-title":"Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant","volume":"99","author":"Maximova","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0039","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12887-020-02028-6","article-title":"Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis","volume":"20","author":"Feng","year":"2020","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0041","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0042","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","article-title":"High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen","volume":"14","author":"Geddes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0043","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.bmt.1703047","article-title":"Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation","volume":"27","author":"Copelan","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0044","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1 suppl 1","key":"10.1016\/j.bbmt.2020.08.006_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbmt.2007.10.008","article-title":"The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cooke","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0046","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2019000143","article-title":"Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions","volume":"3","author":"Pagliuca","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0047","first-page":"3599","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0048","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0301-472X(03)00070-5","article-title":"Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation","volume":"31","author":"Moscard\u00f3","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0049","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.14727","article-title":"Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation","volume":"178","author":"Richardson","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0051","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0052","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","article-title":"Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD)","volume":"54","author":"Yoon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0053","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.23383","article-title":"American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009","volume":"51","author":"Boyer","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0054","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2006-941447","article-title":"Transjugular intrahepatic portosystemic shunt-related complications and practical solutions","volume":"23","author":"Ripamonti","year":"2006","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0056","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cld.2011.12.008","article-title":"Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt","volume":"16","author":"Riggio","year":"2012","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0057","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2014-03-551630","article-title":"How I treat sinusoidal obstruction syndrome","volume":"123","author":"Chao","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0058","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0059","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","article-title":"Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation","volume":"17","author":"Palomo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.08.006_bib0060","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:14:11Z","timestamp":1761059651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1083879120304742"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.006","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome (VOD\/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}